TENAYA THERAPEUTICS, INC. TNYA 深 滬
等待開盤 10-28 09:30:00 美东时间
1.656
-0.004
-0.24%
華盛通- 最 高1.70
- 今 開1.66
- 成交量 404.66万股
- 最 低 1.55
- 昨 收 1.66
- 總市值 2.70亿
- 52周最高 4.01
- 市盈率 靜 --
- 換手率 2.48%
- 52周最低 0.36
- 委 比 39.11%
- 總股本 1.63亿
- 歷史最高 32.00
- 量 比 1.18
- 振 幅 9.04%
- 歷史最低 0.36
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
<p>Tenaya Therapeutics announced that CEO Faraz Ali will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. Additionally, management will host virtual 1x1 meetings on October 15. The fireside chat webcast and replay can be accessed via Tenaya's website under the Investors section. Tenaya focuses on developing curative therapies for heart diseases, with a pipeline including gene therapie...
10-09 20:05
Tenaya Therapeutics to Participate in Upcoming October Investor Conferences
<p><p align="left">Tenaya Therapeutics的CEO Faraz Ali将参加10月6日的Cell & Gene Meeting on the Mesa会议，参与"Future Horizons"小组讨论和公司展示。此外，他在10月21日的Chardan Annual Genetic Medicines Conference上将参与"Gene Therapies for Genetic Cardiac Diseases"小组讨论。这两场会议均提供网络直播，直播存档可在Tenaya官网保存约30天。Tenaya专注于心脏疾病基因治疗，旗下有多个临床阶段候选药物。如需更多信息，请访问公司官网或联系相关人员。</p></p>
10-02 20:05
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics granted stock options to purchase 202,000 shares of its common stock to two new non-executive employees. The options, exercisable at $1.20 per share, vest over four years and are subject to the company's 2024 Inducement Equity Incentive Plan. The options, granted as inducements under NASDAQ Listing Rule 5635(c)(4), reflect the company's mission to develop curative therapies for heart disease.
09-18 20:05
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Tenaya Therapeutics' CEO, Faraz Ali, will participate in a fireside chat at Morgan Stanley's 23rd Annual Global Healthcare Conference on September 9, 2025. The event will be webcast live and available for replay on Tenaya's website. Tenaya focuses on developing curative therapies for heart disease, with a pipeline including gene therapies TN-201 and TN-401, and small molecule HDAC6 inhibitor TN-301. For more details, visit their website or contac...
09-02 20:05
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Tenaya Therapeutics presented interim data from its MyClimb study, the largest noninterventional natural history study of pediatric participants with MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the European Society of Cardiology Congress. The study highlights the severe risks and rapid progression of the disease, particularly in nonobstructive HCM, which lacks approved treatments. Key findings include: 93% of participants had nonobstr...
08-31 14:15
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
08-27 18:15
Analysts’ Top Healthcare Picks: Tenaya Therapeutics (TNYA), Nexalin Technology, Inc. (NXL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-21 17:03
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics' CEO, Faraz Ali, will speak at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will be webcast live and available via the Investors section of Tenaya's website, with an archive for 30 days. Tenaya focuses on developing curative therapies for heart diseases, with clinical-stage candidates TN-201 and TN-401 targeting genetic cardiomyopathies. The company leverages genetic insights and innovative...
08-08 12:00
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
08-07 20:50
